News – Page 1100 – Endpoints News

Eli Lilly slashes R&D jobs, shutters 2 research sites as it looks to cut 3,500 staffers worldwide

8 years ago

Bristol-Myers' checkpoint combo scores in PhIII study; AstraZeneca hands Circassia positive data for COPD drug; ...

8 years ago

AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis

8 years ago

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

8 years ago

Alnylam slammed after patient death forces investigators to halt dosing of fitusiran, raising new safety fears

8 years ago

Google helps boost Gritstone’s neoantigen R&D gamble to $195M as researchers prep for first human study

8 years ago

As China biotech booms, Fidelity group rolls out $250M fund with a big focus on drug R&D

8 years ago

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug

8 years ago

Safety fears spur FDA to pause checkpoint combo studies by Bristol-Myers, Celgene

8 years ago

How your company can fund the work at Endpoints News — and give your employees complete access to our content

8 years ago

Publisher's note

Bioverativ climbs on board Bicycle's peptide platform in discovery deal; Ironwood CFO jumps ship, joins Vertex

8 years ago

Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD

8 years ago

Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall

8 years ago

Merck snaps up a German immuno-oncology upstart in a $603M bolt-on deal

8 years ago

Voyager Therapeutics adds proof its gene therapy for Parkinson's can work, shares soar

8 years ago

Verastem's low-stakes comeback gamble on an AbbVie/Infinity castoff pays off with positive CLL data

8 years ago

Here’s the inside account of Gilead's 11-week sprint to its $12B Kite buyout

8 years ago

ASCO spotlight presaged two more biotech IPOs angling for $215M

8 years ago

Cancer vax biotech Amal grabs $10M round; Global Blood Therapeutics eyes PRV with new FDA designation

8 years ago

OrbiMed lines up $551M gamble on China, India biotech sectors

8 years ago

Insmed shares soar as PhIII lung disease study proves positive, pointing to quick FDA pitch

8 years ago

Emboldened by recent R&D successes, Merck KGaA looks at selling off $1B-plus consumer division

8 years ago

In staggering setback, toxic reaction kills Cellectis’ first CAR-T patient, forcing trial halt

8 years ago

Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors

8 years ago

First page Previous page 1097 1098 109911001101 1102 1103 Next page Last page